OBJECTIVES: Psoriasis (PsO) is not curable; however, for many people treatment will help to control the disease. This study provides information on the current supply with biological agents and its related costs in Germany. METHODS: A retrospective claims data analysis was conducted utilizing the Institute for Applied Health Research (InGef) Berlin, formerly HRI Health Risk Institute, database including approximately 6.7 million insured anonymities originating from 63 statutory health insurances. Analyses were performed by the InGef institute. A sample with approximately 4 million insured persons was drawn and stratified by age and gender according to the official demographic structure of the German statutory health insured population (DeStatis, Dec 31^st, 2013). Patient data from 2012 - 2016 were included if they met the following conditions: Main diagnosis of PsO (ICD-10 code L40.-), and start / maintenance / switch of treatment with PsO approved biological agent(s) (at least for three months). The study evaluated hospital admission, change in medication and direct medical costs (drug, outpatient care, hospitalization). RESULTS: Leading biological agents for 1^st line treatment of PsO are adalimumab and apremilast, however, at a low level of share of prescriptions. Adalimumab and etanercept are administered mostly to patients already on treatment (in 2015 adalimumab 40.4 % vs. etanercept 26.6 %). The total costs of the included 2’041 patients add up to € 36’874’827 in 2015. The total number of patients, the number of hospital admissions and the total treatment costs including all individual cost items grew yearly on average between 1.7% and 14.5 % (2012 – 2015). Hospitalization per patient declined slightly from 0.8 to 0.7. CONCLUSIONS: Adalimumab, apremilast and etanercept are those biological agents mainly used for treating PsO. All cost items grew steadily over the last 4 years. Total costs in 2015 were € 36.9 million (on average € 18’067 per patient).